Finance

Lists
Why is CABA down 3.76%?
Dive Deeper
CABA:NASDAQ
Cabaletta Bio Inc
$1.28
-3.76%
(-0.050) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CABA...
Open
$1.34
High
$1.35
Low
$1.25
Mkt. cap
276.12M
Avg. vol.
4.79M
Volume
3.23M
52-wk high
$4.23
52-wk low
$1.18
EPS
-$1.41
Beta
3.56
Shares outstanding
215.72M
No. of employees
157
Open
$1.34
High
$1.35
Low
$1.25
Mkt. cap
276.12M
Avg. vol.
4.79M
Volume
3.23M
52-wk high
$4.23
52-wk low
$1.18
EPS
-$1.41
Beta
3.56
Shares outstanding
215.72M
No. of employees
157
News stories
From web sources and news partners
About Cabaletta Bio Inc
CEO-
Employees157
Founded2017
HeadquartersPhiladelphia, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 5 analysts giving stock ratings to CABA in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CABA in the last 3 months.
Highest
Current $1.28
$16.00 (+1,150.00%)
Average
$10.00 (+681.25%)
Lowest
$3.00 (+134.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Samantha Semenkow
Citi
Buy
Maintained
$8.00
+525%
11/10/2026
Michael Ulz
Morgan Stanley
Buy
Maintained
$13.00
+915.6%
11/06/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$16.00
+1,150%
11/06/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
09/02/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$3.00
+134.4%
09/01/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$30.00
+2,243.8%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$16.00
+1,150%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Roger Song
Jefferies
Buy
Maintained
$14.00
+993.8%
03/23/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.28 / -$0.31
+8.47%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
36.19M
37.35M
44.43M
47.14M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.42M
6.94M
7.59M
7.56M
Operating expense
42.61M
44.30M
52.02M
54.71M
Total operating expenses
42.61M
44.30M
52.02M
54.71M
Operating income
-42.61M
-44.30M
-52.02M
-54.71M
Other non operating income
-79.00K
341.00K
-84.00K
21.00K
EBT including unusual items
-41.92M
-43.52M
-51.02M
-53.05M
EBT excluding unusual items
-41.92M
-43.52M
-51.02M
-53.05M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-41.92M
-43.52M
-51.02M
-53.05M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.39
-0.34
-0.28
Interest and investment income
1.33M
1.08M
1.60M
2.14M
Interest expense
-555.00K
-636.00K
-517.00K
-511.00K
Net interest expenses
771.00K
440.00K
1.09M
1.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.26M
-43.96M
-51.65M
-54.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps